vegf elisa assay kit Search Results


86
Servicebio Inc rat tnf α elisa kit
Inflammatory cytokine levels in the gastrocnemius muscle of rats in each group. ( a ) IL-1β; ( b ) IL-6; ( c ) <t>TNF-α;</t> ( d ) TGF-β (n = 4). Data are presented as mean ± SEM. Differences between groups were compared using one-way ANOVA. * p < 0.05, ns p > 0.05.
Rat Tnf α Elisa Kit, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc13265405-47-54-58?v=Servicebio+Inc
Average 86 stars, based on 1 article reviews
rat tnf α elisa kit - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

93
Boster Bio human vegf vegfa elisa kit
Inflammatory cytokine levels in the gastrocnemius muscle of rats in each group. ( a ) IL-1β; ( b ) IL-6; ( c ) <t>TNF-α;</t> ( d ) TGF-β (n = 4). Data are presented as mean ± SEM. Differences between groups were compared using one-way ANOVA. * p < 0.05, ns p > 0.05.
Human Vegf Vegfa Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pm41903748-82-13-17?v=Boster+Bio
Average 93 stars, based on 1 article reviews
human vegf vegfa elisa kit - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
Elabscience Biotechnology vegf
Figure 2. mRNA expression levels of <t>VEGF</t> and MMP‑13 in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Relative mRNA expression levels of VEGF in the medial articular cartilage. (B) Relative mRNA expression levels of MMP‑13 in the medial articular cartilage. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; MMP‑13, matrix metalloproteinase‑13; Th, thalidomide; VEGF, vascular endothelial growth factor.
Vegf, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pm29750304-44-4-9?v=Elabscience+Biotechnology
Average 94 stars, based on 1 article reviews
vegf - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

95
Elabscience Biotechnology vegf a elsa kit
Figure 2. mRNA expression levels of <t>VEGF</t> and MMP‑13 in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Relative mRNA expression levels of VEGF in the medial articular cartilage. (B) Relative mRNA expression levels of MMP‑13 in the medial articular cartilage. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; MMP‑13, matrix metalloproteinase‑13; Th, thalidomide; VEGF, vascular endothelial growth factor.
Vegf A Elsa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc12180182-103-2-5?v=Elabscience+Biotechnology
Average 95 stars, based on 1 article reviews
vegf a elsa kit - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

94
Diaclone human elisa kit
Figure 2. mRNA expression levels of <t>VEGF</t> and MMP‑13 in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Relative mRNA expression levels of VEGF in the medial articular cartilage. (B) Relative mRNA expression levels of MMP‑13 in the medial articular cartilage. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; MMP‑13, matrix metalloproteinase‑13; Th, thalidomide; VEGF, vascular endothelial growth factor.
Human Elisa Kit, supplied by Diaclone, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc05634974-67-3-2?v=Diaclone
Average 94 stars, based on 1 article reviews
human elisa kit - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
R&D Systems quantiglo chemiluminescent elisas humanvegf
Figure 2. mRNA expression levels of <t>VEGF</t> and MMP‑13 in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Relative mRNA expression levels of VEGF in the medial articular cartilage. (B) Relative mRNA expression levels of MMP‑13 in the medial articular cartilage. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; MMP‑13, matrix metalloproteinase‑13; Th, thalidomide; VEGF, vascular endothelial growth factor.
Quantiglo Chemiluminescent Elisas Humanvegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pm37127039-58-7-12?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
quantiglo chemiluminescent elisas humanvegf - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

90
R&D Systems human vegf elisa kit
Changes in plasma vascular endothelial growth factor <t>(VEGF)</t> concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint
Human Vegf Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc07110289-65-8-12?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
human vegf elisa kit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
R&D Systems human vegf 165 elisa kit
Changes in plasma vascular endothelial growth factor <t>(VEGF)</t> concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint
Human Vegf 165 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc02998412-141-28-33?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human vegf 165 elisa kit - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

94
R&D Systems mouse vegf elisa kit
Changes in plasma vascular endothelial growth factor <t>(VEGF)</t> concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint
Mouse Vegf Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc03034849-254-12-16?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
mouse vegf elisa kit - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

96
R&D Systems mouse vegf quantikine elisa kit
Combination therapy of the CITED2 peptide and aflibercept rescues retinal neovascularization and vaso-obliteration in OIR. (A) Immunofluorescent staining of OIR retinas at P17 after intravitreal injection of aflibercept (200 ng), aflibercept and CITED2 peptide (200 ng aflibercept and 3.4 ng CITED2 peptide), or CITED2 peptide (3.4 ng) at P12. Retinal whole mounts were stained with GS-lectin. Representative images for each treatment are shown (Upper) and the same images are shown (Lower) with NV highlighted in red and VO highlighted in yellow as used for quantification. (Scale bars, 1 mm.) (B) Quantification of the percentage of VO area in whole retinas. (C) Quantification of the percentage of NV area in whole retinas. For B and C, n > 7 per group. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) Validation of expression of HIF target genes in CITED2- and aflibercept-treated OIR retinas. Total RNA was isolated 24 h after intravitreal injection of CITED2 peptide (3.4 ng) or aflibercept (10 μg) on P12 (n = 6 per group). P values were calculated using multiple t tests. **P < 0.01, ***P < 0.001, ****P < 0.0001. (E) Quantification of <t>VEGF</t> protein levels in P15 retinas by <t>ELISA</t> (n = 6 per group). P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, ****P < 0.0001. For B–E, the mean and SEM are shown in red.
Mouse Vegf Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc07668029-250-10-15?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
mouse vegf quantikine elisa kit - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
R&D Systems vascular endothelial growth factor
Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human <t>endothelial</t> cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor <t>(VEGF;</t> 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).
Vascular Endothelial Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/pmc12872546-37-41-51?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
vascular endothelial growth factor - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

93
Elabscience Biotechnology plasma human vegf
Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human <t>endothelial</t> cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor <t>(VEGF;</t> 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).
Plasma Human Vegf, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vegf+elisa+assay+kit/10__21767_slash_2386___5180__1000107-52-12-17?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
plasma human vegf - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


Inflammatory cytokine levels in the gastrocnemius muscle of rats in each group. ( a ) IL-1β; ( b ) IL-6; ( c ) TNF-α; ( d ) TGF-β (n = 4). Data are presented as mean ± SEM. Differences between groups were compared using one-way ANOVA. * p < 0.05, ns p > 0.05.

Journal: Journal of Pain Research

Article Title: Effects and Mechanisms of Wrist-Ankle Acupuncture on Inflammatory Pain in the Rat Gastrocnemius Muscle

doi: 10.2147/JPR.S605568

Figure Lengend Snippet: Inflammatory cytokine levels in the gastrocnemius muscle of rats in each group. ( a ) IL-1β; ( b ) IL-6; ( c ) TNF-α; ( d ) TGF-β (n = 4). Data are presented as mean ± SEM. Differences between groups were compared using one-way ANOVA. * p < 0.05, ns p > 0.05.

Article Snippet: Complete freund’s adjuvant (CFA) (Sigma, USA, F5881), trichloroethanol (Aibei, Nanjing, CN, M2820), acupuncture needles (Jiajian Medical, CN), TENS-WAA equipment (Shanghai MicroPort Scientific Co, CN), Von Frey hairs mechanical stimulation needles (Yuyan Instrument, CN), Von Frey test cage (Yuyan Instrument, CN), Rat IL-6 ELISA Kit (Servicebio, CN, GER0001-96T), Rat IL-1β ELISA Kit (Servicebio, CN, GER0002-96T), Rat TNF-α ELISA Kit (Servicebio, CN, GER0004-96T), Rat TGF-β1 ELISA Kit (Servicebio, CN, GER0051-96T), BCA Protein Assay Kit (Servicebio, CN, G2026-1000T), TRIzol ® reagent (China, Servicebio, CN, G3013) SweScript All-in-One SuperMix for qPCR (Servicebio, CN, G3337), Blue SYBR Green qPCR Master Mix (Servicebio, CN, G3326).

Techniques:

Figure 2. mRNA expression levels of VEGF and MMP‑13 in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Relative mRNA expression levels of VEGF in the medial articular cartilage. (B) Relative mRNA expression levels of MMP‑13 in the medial articular cartilage. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; MMP‑13, matrix metalloproteinase‑13; Th, thalidomide; VEGF, vascular endothelial growth factor.

Journal: Molecular medicine reports

Article Title: Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice.

doi: 10.3892/mmr.2018.8980

Figure Lengend Snippet: Figure 2. mRNA expression levels of VEGF and MMP‑13 in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Relative mRNA expression levels of VEGF in the medial articular cartilage. (B) Relative mRNA expression levels of MMP‑13 in the medial articular cartilage. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; MMP‑13, matrix metalloproteinase‑13; Th, thalidomide; VEGF, vascular endothelial growth factor.

Article Snippet: An ELISA kit of VEGF (E-EL-M1292c) was purchased from Elabscience Biotechnology Co., Ltd., Wuhan, China.

Techniques: Expressing, Standard Deviation

Figure 3. Immunohistochemical analysis of VEGF expression in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Immunohistochemistry staining of VEGF in the articular cartilage of the medial tibial plateau (magnification, x400, scale bar=100 µm). (B) Quantification of VEGF positive cells, based on the results of immunohistochemistry staining. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; Th, thalidomide; VEGF, vascular endothelial growth factor.

Journal: Molecular medicine reports

Article Title: Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice.

doi: 10.3892/mmr.2018.8980

Figure Lengend Snippet: Figure 3. Immunohistochemical analysis of VEGF expression in the knee articular cartilage of mice among the Sham, Dmm and Dmm+Th groups (n=4 in each group). (A) Immunohistochemistry staining of VEGF in the articular cartilage of the medial tibial plateau (magnification, x400, scale bar=100 µm). (B) Quantification of VEGF positive cells, based on the results of immunohistochemistry staining. The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; Th, thalidomide; VEGF, vascular endothelial growth factor.

Article Snippet: An ELISA kit of VEGF (E-EL-M1292c) was purchased from Elabscience Biotechnology Co., Ltd., Wuhan, China.

Techniques: Immunohistochemical staining, Expressing, Immunohistochemistry, Staining, Standard Deviation

Figure 5. ELISA analysis of serum VEGF concentration of mice among the Sham, Dmm and Dmm+Th groups (n=8 in each group). The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; Th, thalidomide; VEGF, vascular endothelial growth factor.

Journal: Molecular medicine reports

Article Title: Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice.

doi: 10.3892/mmr.2018.8980

Figure Lengend Snippet: Figure 5. ELISA analysis of serum VEGF concentration of mice among the Sham, Dmm and Dmm+Th groups (n=8 in each group). The values are presented as the mean ± standard deviation. *P<0.05 compared with the Sham group; #P<0.05 compared with the Dmm group. Dmm, destabilization of the medial meniscus; Th, thalidomide; VEGF, vascular endothelial growth factor.

Article Snippet: An ELISA kit of VEGF (E-EL-M1292c) was purchased from Elabscience Biotechnology Co., Ltd., Wuhan, China.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Standard Deviation

Changes in plasma vascular endothelial growth factor (VEGF) concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint

Journal: Archives of Virology

Article Title: Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

doi: 10.1007/s00705-020-04605-7

Figure Lengend Snippet: Changes in plasma vascular endothelial growth factor (VEGF) concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint

Article Snippet: Plasma concentrations of VEGF were determined using a human VEGF ELISA Kit (R & D Systems, Minneapolis, MN, USA), according to the manufacturer’s protocol.

Techniques: Clinical Proteomics, Concentration Assay

Combination therapy of the CITED2 peptide and aflibercept rescues retinal neovascularization and vaso-obliteration in OIR. (A) Immunofluorescent staining of OIR retinas at P17 after intravitreal injection of aflibercept (200 ng), aflibercept and CITED2 peptide (200 ng aflibercept and 3.4 ng CITED2 peptide), or CITED2 peptide (3.4 ng) at P12. Retinal whole mounts were stained with GS-lectin. Representative images for each treatment are shown (Upper) and the same images are shown (Lower) with NV highlighted in red and VO highlighted in yellow as used for quantification. (Scale bars, 1 mm.) (B) Quantification of the percentage of VO area in whole retinas. (C) Quantification of the percentage of NV area in whole retinas. For B and C, n > 7 per group. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) Validation of expression of HIF target genes in CITED2- and aflibercept-treated OIR retinas. Total RNA was isolated 24 h after intravitreal injection of CITED2 peptide (3.4 ng) or aflibercept (10 μg) on P12 (n = 6 per group). P values were calculated using multiple t tests. **P < 0.01, ***P < 0.001, ****P < 0.0001. (E) Quantification of VEGF protein levels in P15 retinas by ELISA (n = 6 per group). P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, ****P < 0.0001. For B–E, the mean and SEM are shown in red.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: An allosteric peptide inhibitor of HIF-1α regulates hypoxia-induced retinal neovascularization

doi: 10.1073/pnas.2017234117

Figure Lengend Snippet: Combination therapy of the CITED2 peptide and aflibercept rescues retinal neovascularization and vaso-obliteration in OIR. (A) Immunofluorescent staining of OIR retinas at P17 after intravitreal injection of aflibercept (200 ng), aflibercept and CITED2 peptide (200 ng aflibercept and 3.4 ng CITED2 peptide), or CITED2 peptide (3.4 ng) at P12. Retinal whole mounts were stained with GS-lectin. Representative images for each treatment are shown (Upper) and the same images are shown (Lower) with NV highlighted in red and VO highlighted in yellow as used for quantification. (Scale bars, 1 mm.) (B) Quantification of the percentage of VO area in whole retinas. (C) Quantification of the percentage of NV area in whole retinas. For B and C, n > 7 per group. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) Validation of expression of HIF target genes in CITED2- and aflibercept-treated OIR retinas. Total RNA was isolated 24 h after intravitreal injection of CITED2 peptide (3.4 ng) or aflibercept (10 μg) on P12 (n = 6 per group). P values were calculated using multiple t tests. **P < 0.01, ***P < 0.001, ****P < 0.0001. (E) Quantification of VEGF protein levels in P15 retinas by ELISA (n = 6 per group). P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, ****P < 0.0001. For B–E, the mean and SEM are shown in red.

Article Snippet: Supernatants were then assayed without dilution in duplicate using the Mouse VEGF Quantikine ELISA kit (R&D Systems) according to the manufacturer’s protocol.

Techniques: Staining, Injection, Biomarker Discovery, Expressing, Isolation, Enzyme-linked Immunosorbent Assay

Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human endothelial cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor (VEGF; 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human endothelial cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor (VEGF; 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: MTT Assay, Control, Migration, Wound Healing Assay

Nicotine-free eVape exposure causes significant upregulation of angiopoietin-2, endoglin, placental growth factor (PIGF), and VEGF as well as significant downregulation of endothelial growth factor (EGF) and prolactin in endothelial cells. HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h. (a–c) Cell lysates were used for the Proteome Profiler Angiogenesis array membranes. Changes in the expression of all angiogenesis-related proteins in array (a) (ii) were quantified using the membranes (representative image in (a) (i) ). Specific analyses of the (b) upregulation and (c) downregulation of angiogenesis-related proteins on the membranes were quantified. (d) mRNA expression of angiopoietin-2, EGF, endoglin, PIGF, prolactin, and VEGF were measured by RT-PCR using specific primers. (e) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays. The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Nicotine-free eVape exposure causes significant upregulation of angiopoietin-2, endoglin, placental growth factor (PIGF), and VEGF as well as significant downregulation of endothelial growth factor (EGF) and prolactin in endothelial cells. HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h. (a–c) Cell lysates were used for the Proteome Profiler Angiogenesis array membranes. Changes in the expression of all angiogenesis-related proteins in array (a) (ii) were quantified using the membranes (representative image in (a) (i) ). Specific analyses of the (b) upregulation and (c) downregulation of angiogenesis-related proteins on the membranes were quantified. (d) mRNA expression of angiopoietin-2, EGF, endoglin, PIGF, prolactin, and VEGF were measured by RT-PCR using specific primers. (e) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays. The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay

Activation of ARF6 by its guanine nucleotide exchange factor (ARNO) regulates angiogenic processes in endothelial cells induced by nicotine-free eVape. (a, b) HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h, and the cell lysates were analysed by Western blotting for (a) ARF6 or (b) ARNO expression. The Western blotting membranes (representative blots are shown in (i) ) were quantified and normalised to the actin expression shown in (ii) . (c–f) HUVECs were treated with ARF6 inhibitor (NAV2729; 5 µM), ARNO inhibitor (Secin H3; 10 µM), or dimethyl sulfoxide (DMSO) as vehicle control at the same time as eVape exposure. (c) ROS accumulation was assessed by DCFDA incorporation (fluorescence at 485/535 nm) following 2 h of treatment. (d) Cell adhesion, (e) migration, and (f) angiogenic potential were measured following (d, e) 6 h and (f) 24 h of treatments. (g) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays following 24 h of treatment with 2% nicotine-free eVape fluid in the presence (closed circles) and absence (open circles) of Secin H3 (10 µM). The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for NAV2729 and Secin H3 (DMSO).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Activation of ARF6 by its guanine nucleotide exchange factor (ARNO) regulates angiogenic processes in endothelial cells induced by nicotine-free eVape. (a, b) HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h, and the cell lysates were analysed by Western blotting for (a) ARF6 or (b) ARNO expression. The Western blotting membranes (representative blots are shown in (i) ) were quantified and normalised to the actin expression shown in (ii) . (c–f) HUVECs were treated with ARF6 inhibitor (NAV2729; 5 µM), ARNO inhibitor (Secin H3; 10 µM), or dimethyl sulfoxide (DMSO) as vehicle control at the same time as eVape exposure. (c) ROS accumulation was assessed by DCFDA incorporation (fluorescence at 485/535 nm) following 2 h of treatment. (d) Cell adhesion, (e) migration, and (f) angiogenic potential were measured following (d, e) 6 h and (f) 24 h of treatments. (g) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays following 24 h of treatment with 2% nicotine-free eVape fluid in the presence (closed circles) and absence (open circles) of Secin H3 (10 µM). The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for NAV2729 and Secin H3 (DMSO).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: Activation Assay, Western Blot, Expressing, Control, Fluorescence, Migration, Enzyme-linked Immunosorbent Assay